» Articles » PMID: 36331921

"Let's See What Happens:"-Women's Experiences of Open-label Placebo Treatment for Menopausal Hot Flushes in a Randomized Controlled Trial

Overview
Journal PLoS One
Date 2022 Nov 4
PMID 36331921
Authors
Affiliations
Soon will be listed here.
Abstract

Open-label (honestly prescribed) placebos are an ethical way to evoke placebo effects in patients. As part of a mixed-methods study, we conducted in-depth interviews with eight menopausal women who underwent and benefitted from open-label placebo treatment in a randomized-controlled trial of hot flushes. Data were analyzed using Interpretative Phenomenological Analysis. We found that the women had low expectations about the placebo treatment yet endorsed what they referred to as "hope" and openness to "see what happens". Recording hot flushes via the symptom diary was viewed as a valuable opportunity for self-examination and appraising outcomes. Receiving relief from the placebo treatment empowered women and enhanced their sense of control and agency. In summary, participants' initial openness towards placebos, their hopes to get better, monitoring symptoms closely, and taking the initiative to address symptoms were components of a positive open-label placebo experience.

Citing Articles

Preoperative Anxiolysis and Treatment Expectation (PATE Trial): open-label placebo treatment to reduce preoperative anxiety in female patients undergoing gynecological laparoscopic surgery - study protocol for a bicentric, prospective,....

Wessels J, Klinger R, Benson S, Brenner T, Zollner C, Elsenbruch S Front Psychiatry. 2024; 15:1396562.

PMID: 39045553 PMC: 11265268. DOI: 10.3389/fpsyt.2024.1396562.


Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2).

Santoro N, Nappi R, Neal-Perry G, English M, King D, Yamaguchi Y Menopause. 2024; 31(4):247-257.

PMID: 38517210 PMC: 11896090. DOI: 10.1097/GME.0000000000002340.


A qualitative study of imaginary pills and open-label placebos in test anxiety.

Buergler S, Sezer D, Busch A, Enzmann M, Bakis B, Locher C PLoS One. 2023; 18(9):e0291004.

PMID: 37656757 PMC: 10473493. DOI: 10.1371/journal.pone.0291004.

References
1.
Leung K, Silvius J, Pimlott N, Dalziel W, Drummond N . Why health expectations and hopes are different: the development of a conceptual model. Health Expect. 2009; 12(4):347-60. PMC: 5060505. DOI: 10.1111/j.1369-7625.2009.00570.x. View

2.
Corbett M, Foster N, Ong B . Living with low back pain-Stories of hope and despair. Soc Sci Med. 2007; 65(8):1584-94. DOI: 10.1016/j.socscimed.2007.06.008. View

3.
. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause. 2015; 22(11):1155-72. DOI: 10.1097/GME.0000000000000546. View

4.
Kaptchuk T, Friedlander E, Kelley J, Sanchez M, Kokkotou E, Singer J . Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One. 2011; 5(12):e15591. PMC: 3008733. DOI: 10.1371/journal.pone.0015591. View

5.
Eaves E, Sherman K, Ritenbaugh C, Hsu C, Nichter M, Turner J . A qualitative study of changes in expectations over time among patients with chronic low back pain seeking four CAM therapies. BMC Complement Altern Med. 2015; 15:12. PMC: 4322442. DOI: 10.1186/s12906-015-0531-9. View